Pages that link to "Q33256349"

The following pages link to The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity (Q33256349):

Displaying 41 items.

• Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions. (Q30234940) (← links)
• Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer (Q34281216) (← links)
• Marginal increase of sunitinib exposure by grapefruit juice (Q34594877) (← links)
• Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment (Q34608990) (← links)
• Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction (Q34819051) (← links)
• Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2 (Q35001199) (← links)
• Effect of ABCC2 (MRP2) transport function on erythromycin metabolism (Q35902300) (← links)
• OATP1B1 polymorphism as a determinant of erythromycin disposition (Q36339094) (← links)
• Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease (Q36634909) (← links)
• Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach (Q36720920) (← links)
• The clinical implications of ageing for rational drug therapy (Q37052681) (← links)
• Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing (Q37076331) (← links)
• Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. (Q37176032) (← links)
• Part II: Liver function in oncology: towards safer chemotherapy use. (Q37336474) (← links)
• ESRD impairs nonrenal clearance of fexofenadine but not midazolam (Q37367679) (← links)
• The drug transporter-metabolism alliance: uncovering and defining the interplay (Q37485904) (← links)
• Pharmacokinetics and drug metabolism in the elderly (Q37514319) (← links)
• Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. (Q37657540) (← links)
• Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy (Q37684533) (← links)
• Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? (Q37733572) (← links)
• Drug metabolism in older people--a key consideration in achieving optimal outcomes with medicines. (Q37915843) (← links)
• Breath tests to phenotype drug disposition in oncology (Q38122635) (← links)
• Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis (Q38222867) (← links)
• Alternative Sampling Strategies for Cytochrome P450 Phenotyping. (Q38560254) (← links)
• Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. (Q38627857) (← links)
• CYP3A activity: towards dose adaptation to the individual. (Q38763583) (← links)
• Pharmacokinetic and pharmacodynamic alterations in older people with dementia (Q39275819) (← links)
• Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases (Q40247703) (← links)
• Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers (Q42106492) (← links)
• Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans (Q42864265) (← links)
• Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. (Q43488121) (← links)
• PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics (Q44401287) (← links)
• Effects of uptake and efflux transporter inhibition on erythromycin breath test results (Q46375419) (← links)
• A step closer to personalized chemotherapy: consideration of the influence of genetic variation in hepatic uptake transporters on the metabolism of CYP3A substrates (Q46709769) (← links)
• Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice (Q46954005) (← links)
• CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin (Q48098073) (← links)
• Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz (Q50894716) (← links)
• Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test (Q57265718) (← links)
• The Use of 13C–Erythromycin as an in vivo Probe to Evaluate CYP3A-mediated Drug Interactions in Rats (Q84208178) (← links)
• Pharmacokinetics of erythromycin after intravenous, intramuscular and oral administration to cats (Q84778090) (← links)
• Chronic inhibition of CYP3A is temporarily reduced by each hemodialysis session in patients with end-stage renal disease (Q94477979) (← links)